JP2015531244A - タンパク質を製造するための哺乳動物細胞培養方法 - Google Patents

タンパク質を製造するための哺乳動物細胞培養方法 Download PDF

Info

Publication number
JP2015531244A
JP2015531244A JP2015536976A JP2015536976A JP2015531244A JP 2015531244 A JP2015531244 A JP 2015531244A JP 2015536976 A JP2015536976 A JP 2015536976A JP 2015536976 A JP2015536976 A JP 2015536976A JP 2015531244 A JP2015531244 A JP 2015531244A
Authority
JP
Japan
Prior art keywords
protein
cell culture
cell
cells
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015536976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531244A5 (enExample
Inventor
ティエン・ジュン
マイケル・ボリス
ジェンジアン・リ
ニコラス・アブアブシ
アンジェラ・オー
ナン−シン・チエン
シャオ−ピン・ダイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50000068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015531244(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2015531244A publication Critical patent/JP2015531244A/ja
Publication of JP2015531244A5 publication Critical patent/JP2015531244A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015536976A 2012-10-15 2013-10-14 タンパク質を製造するための哺乳動物細胞培養方法 Pending JP2015531244A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261713812P 2012-10-15 2012-10-15
US61/713,812 2012-10-15
US201361888647P 2013-10-09 2013-10-09
US61/888,647 2013-10-09
PCT/US2013/064758 WO2014062535A1 (en) 2012-10-15 2013-10-14 Mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
JP2015531244A true JP2015531244A (ja) 2015-11-02
JP2015531244A5 JP2015531244A5 (enExample) 2016-09-29

Family

ID=50000068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536976A Pending JP2015531244A (ja) 2012-10-15 2013-10-14 タンパク質を製造するための哺乳動物細胞培養方法

Country Status (5)

Country Link
EP (1) EP2906683B1 (enExample)
JP (1) JP2015531244A (enExample)
CN (1) CN104822826B (enExample)
ES (1) ES2633960T3 (enExample)
WO (1) WO2014062535A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500878A (ja) * 2016-01-06 2019-01-17 オンコバイオロジクス，インコーポレイティド モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
WO2017083224A1 (en) * 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
SG11202003354VA (en) * 2017-10-13 2020-05-28 Boehringer Ingelheim Int Perfusion medium

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
JP2008513425A (ja) * 2004-09-17 2008-05-01 ドマンティス リミテッド Ｃｄ４０ｌ結合のための一価組成物および使用方法
WO2008141207A1 (en) * 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
WO2012023085A1 (en) * 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
ES2255765T3 (es) 1998-05-29 2006-07-01 Genentech, Inc. Procedimiento de cultivo de celulas para la produccion de glicoproteinas.
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
US6413744B1 (en) 1999-08-25 2002-07-02 Immunex Corporation Methods and host cells for improved cell culture
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2003046162A2 (en) 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
US8678606B2 (en) 2010-06-14 2014-03-25 Aja Berger Carrying container with at least two light sources
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
JP2008513425A (ja) * 2004-09-17 2008-05-01 ドマンティス リミテッド Ｃｄ４０ｌ結合のための一価組成物および使用方法
WO2008141207A1 (en) * 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
WO2012023085A1 (en) * 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 280, JPN6017028965, 2001, pages 221 - 228, ISSN: 0003780593 *
BRIAN RASMUSSEN, CYTOTECHNOLOGY, vol. V28 N1-3, JPN5015010816, 1 September 1998 (1998-09-01), DO, pages 31 - 42, ISSN: 0003612026 *
INN H.Y. YUK, BIOTECHNOLOGY AND BIOENGINEERING, vol. V79 N1, JPN5015010814, 5 July 2002 (2002-07-05), pages 74 - 82, ISSN: 0003780592 *
JONG KWANG HONG, JOURNAL OF BIOTECHNOLOGY, vol. V155 N2, JPN5015010815, 17 June 2011 (2011-06-17), NL, pages 225 - 231, ISSN: 0003612025 *
MORRIS ARVIA E: "EFFECTS OF INSULIN AND LONGR3 以下省略", BIOTECHNOLOGY PROGRESS, vol. V16 N5, JPN5015010817, 1 January 2000 (2000-01-01), US, pages 693 - 697, ISSN: 0003612024 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500878A (ja) * 2016-01-06 2019-01-17 オンコバイオロジクス，インコーポレイティド モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減

Also Published As

Publication number Publication date
ES2633960T3 (es) 2017-09-26
EP2906683A1 (en) 2015-08-19
EP2906683B1 (en) 2017-05-31
CN104822826A (zh) 2015-08-05
WO2014062535A1 (en) 2014-04-24
CN104822826B (zh) 2019-04-30

Similar Documents

Publication Publication Date Title
KR101402634B1 (ko) 항-노화 화합물을 이용한 단백질 제조 방법
CN102753572A (zh) 应用糖皮质激素在哺乳动物细胞培养物中生产糖蛋白的方法
US12410457B2 (en) Use of rosmarinic acid in cell bioproduction
EP2906683B1 (en) Mammalian cell culture processes for protein production
US9340592B2 (en) CHO/CERT cell lines
CN111465686A (zh) 动物细胞、动物细胞的制造方法及靶蛋白的制造方法
JP2022550315A (ja) 濃縮灌流培地
KR20080003384A (ko) ｈＣＭＶ 주요 즉각 조기 유전자의 제 1 인트론 및ｍＣＭＶ 프로모터를 포함한 포유동물 발현 벡터
CA2852021C (en) Addition of iron to improve cell culture
US20130150554A1 (en) Cell culture of growth factor-free adapted cells
US20170327558A1 (en) Mammalian cell culture processes for protein production
JP6697442B2 (ja) 真核細胞の比生産速度を増加させる方法
CN106414719A (zh) 生物反应器中重组von Willebrand因子的改进生产
KR20240054986A (ko) Igf- 배지에 대한 플랫폼 숙주의 적응

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180424